FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2370-2372 December 2, 2004 Number 23 Next

Disruption of C/EBP Function in Acute Myeloid Leukemia

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Smith, M. L. PubMed Citation

In acute myeloid leukemia (AML), the most common type of acute leukemia in adults, there is clonal expansion and arrested maturation of myeloid precursor cells in the bone marrow, frequently resulting in granulocytopenia, thrombocytopenia, and anemia. The genetic abnormalities underlying these events fall into distinct classes. One class arises from mutations that affect lineage-specific transcription factors involved in hematopoietic-cell differentiation.^1,2 These mutations, which disrupt cellular differentiation, are crucial events in the pathogenesis of a subgroup of cases of AML. Another class of genetic events comprises mutations that affect intracellular signaling molecules in a way that enhances cell proliferation and survival . . . [Full Text of this Article]

Source Information

From the Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.

This article has been cited by other articles:

• Langer, C., Radmacher, M. D., Ruppert, A. S., Whitman, S. P., Paschka, P., Mrozek, K., Baldus, C. D., Vukosavljevic, T., Liu, C.-G., Ross, M. E., Powell, B. L., de la Chapelle, A., Kolitz, J. E., Larson, R. A., Marcucci, G., Bloomfield, C. D. (2008). High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111: 5371-5379 [Abstract] [Full Text]  
• Hackanson, B., Bennett, K. L., Brena, R. M., Jiang, J., Claus, R., Chen, S.-S., Blagitko-Dorfs, N., Maharry, K., Whitman, S. P., Schmittgen, T. D., Lubbert, M., Marcucci, G., Bloomfield, C. D., Plass, C. (2008). Epigenetic Modification of CCAAT/Enhancer Binding Protein {alpha} Expression in Acute Myeloid Leukemia. Cancer Res. 68: 3142-3151 [Abstract] [Full Text]  
• Stone, R. M. (2008). Genetically Defined Prognostic Factors and Novel Therapeutics for AML. Am Soc Clin Oncol Ed Book 2008: 280-284 [Abstract] [Full Text]  
• Chung, K. Y., Morrone, G., Schuringa, J. J., Plasilova, M., Shieh, J.-H., Zhang, Y., Zhou, P., Moore, M. A.S. (2006). Enforced Expression of NUP98-HOXA9 in Human CD34+ Cells Enhances Stem Cell Proliferation. Cancer Res. 66: 11781-11791 [Abstract] [Full Text]